{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:31:31Z","timestamp":1793363491833,"version":"4.5.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00911-5","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:06:23Z","timestamp":1777367183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted protein degradation for fetal hemoglobin induction: a new paradigm in \u03b2-hemoglobinopathy therapy"],"prefix":"10.1186","volume":"14","author":[{"given":"Sanjana","family":"Arji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadila","family":"ElMahdaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayana","family":"Bahadur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Chuen Peter","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Konshina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burhanudin","family":"Ayubali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"911_CR1","doi-asserted-by":"publisher","unstructured":"Liu J, Park K, Shen Z, Ye Y, Lee E, Herman R, et al. Exploring novel strategies to alleviate symptoms of \u03b2-Globinopathies: Examining the potential role of embryonic \u03b5-globin induction. Transfus Med Rev. 2024;38:150861. https:\/\/doi.org\/10.1016\/j.tmrv.2024.150861.","DOI":"10.1016\/j.tmrv.2024.150861"},{"key":"911_CR2","doi-asserted-by":"publisher","unstructured":"Aleluia M, Santiago R, da Guarda C, Fonseca T, Neves F, Quinto R, et al. Genetic modulation of fetal hemoglobin in hydroxyurea-treated sickle cell anemia. Am J Hematol. 2017;92 https:\/\/doi.org\/10.1002\/ajh.24680.","DOI":"10.1002\/ajh.24680"},{"key":"911_CR3","doi-asserted-by":"publisher","unstructured":"Manning J, Manning L, Dumoulin A, Padovan J, Chait B. Embryonic and fetal human hemoglobins: structures, oxygen binding, and physiological roles. vertebrate and invertebrate respiratory proteins, lipoproteins and other body fluid proteins. 2020. p. 275\u2013 296 https:\/\/doi.org\/10.1007\/978-3-030-41769-7_11.","DOI":"10.1007\/978-3-030-41769-7_11"},{"key":"911_CR4","doi-asserted-by":"publisher","unstructured":"Liu B, Liu M, Radhakrishnan S, Jaladanki C, Gao C, Tang J, et al. Targeting transcription factors through an IMiD independent zinc finger domain. bioRxiv [Internet]. 2024; https:\/\/doi.org\/10.1101\/2024.01.03.574032.","DOI":"10.1101\/2024.01.03.574032"},{"key":"911_CR5","doi-asserted-by":"publisher","unstructured":"Martyn G, Wienert B, Yang L, Shah M, Norton L, Burdach J, et al. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. Nat Genet. 2018;50:498\u2013503. https:\/\/doi.org\/10.1038\/s41588-018-0085-0.","DOI":"10.1038\/s41588-018-0085-0"},{"key":"911_CR6","doi-asserted-by":"publisher","unstructured":"Ting P, Borikar S, Kerrigan J, Thomsen N, Aghania E, Hinman A, et al. A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction. Sci. 2024;385:91\u20139. https:\/\/doi.org\/10.1126\/science.adk6129.","DOI":"10.1126\/science.adk6129"},{"key":"911_CR7","doi-asserted-by":"publisher","unstructured":"Uda M, Galanello R, Sanna S, Lettre G, Sankaran V, Chen W, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci USA. 2008;105:1620\u20135. https:\/\/doi.org\/10.1073\/pnas.0711566105.","DOI":"10.1073\/pnas.0711566105"},{"key":"911_CR8","doi-asserted-by":"publisher","unstructured":"Shen Y, Verboon J, Zhang Y, Liu N, Kim Y, Marglous S, et al. A unified model of human hemoglobin switching through single-cell genome editing. Nat Commun. 2021;12:4991. https:\/\/doi.org\/10.1038\/s41467-021-25298-9.","DOI":"10.1038\/s41467-021-25298-9"},{"key":"911_CR9","doi-asserted-by":"publisher","unstructured":"Zheng G, Yin M, Mehta S, Chu I-T, Wang S, AlShaye A, et al. A tetramer of BCL11A is required for stable protein production and fetal hemoglobin silencing. Sci. 2024;386:1010\u20138. https:\/\/doi.org\/10.1126\/science.adp3025.","DOI":"10.1126\/science.adp3025"},{"key":"911_CR10","doi-asserted-by":"publisher","unstructured":"Liu N, Hargreaves V, Zhu Q, Kurland J, Hong J, Kim W, et al. Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch. Cell. 2018;173:430-442.e17. https:\/\/doi.org\/10.1016\/j.cell.2018.03.016.","DOI":"10.1016\/j.cell.2018.03.016"},{"key":"911_CR11","doi-asserted-by":"publisher","unstructured":"Yang Y, Ren R, Ly L, Horton J, Li F, Kate G.R. Quinlan, et al. Structural basis for human ZBTB7A action at the fetal globin promoter. Cell Rep. 2021;36:109759. https:\/\/doi.org\/10.1016\/j.celrep.2021.109759.","DOI":"10.1016\/j.celrep.2021.109759"},{"key":"911_CR12","doi-asserted-by":"publisher","unstructured":"Sankaran V, Menne T, Xu J, Akie T, Lettre G, Van Handel B, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Sci. 2008;322:1839\u201342. https:\/\/doi.org\/10.1126\/science.1165409.","DOI":"10.1126\/science.1165409"},{"key":"911_CR13","doi-asserted-by":"publisher","unstructured":"Sankaran V, Xu J, Ragoczy T, Ippolito G, Walkley C, Maika S, et al. Developmental and species-divergent globin switching are driven by BCL11A. Nat. https:\/\/doi.org\/10.1038\/nature08243.","DOI":"10.1038\/nature08243"},{"key":"911_CR14","doi-asserted-by":"publisher","unstructured":"Mehta S, Buyanbat A, Kai Y, Karayel O, Goldman S, Seruggia D, et al. Temporal resolution of gene derepression and proteome changes upon PROTAC-mediated degradation of BCL11A protein in erythroid cells. Cell Chemical Biology. https:\/\/doi.org\/10.1016\/j.chembiol.2022.06.007.","DOI":"10.1016\/j.chembiol.2022.06.007"},{"key":"911_CR15","doi-asserted-by":"publisher","unstructured":"MasudaT, Wang X, Maeda M, Canver M, Sher F, Funnell A, et al. Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science. 2016;351:285\u20139. https:\/\/doi.org\/10.1126\/science.aad3312.","DOI":"10.1126\/science.aad3312"},{"key":"911_CR16","doi-asserted-by":"publisher","unstructured":"Renneville A, Van Galen P, Canver M, McConkey M, Krill-Burger J, Dorfman D, et al. EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood. 2015;126:1930\u20139. https:\/\/doi.org\/10.1182\/blood-2015-06-649087.","DOI":"10.1182\/blood-2015-06-649087"},{"key":"911_CR17","doi-asserted-by":"publisher","unstructured":"Kohne E. Hemoglobinopathies: Clinical manifestations, diagnosis, and treatment. Deutsches \u00c4rzteblatt International. 2011;108:532. https:\/\/doi.org\/10.3238\/arztebl.2011.0532.","DOI":"10.3238\/arztebl.2011.0532"},{"key":"911_CR18","doi-asserted-by":"publisher","unstructured":"Raghupathy R, Manwani D, Little J. Iron overload in sickle cell disease. Adv Hematol. 2010;2010:272940. https:\/\/doi.org\/10.1155\/2010\/272940.","DOI":"10.1155\/2010\/272940"},{"key":"911_CR19","doi-asserted-by":"publisher","unstructured":"Tormey C, Hendrickson J. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood. 2019;133:1821\u201330. https:\/\/doi.org\/10.1182\/blood-2018-08-833962.","DOI":"10.1182\/blood-2018-08-833962"},{"key":"911_CR20","unstructured":"Buerger CS, Jain H. Infectious complications of blood transfusion. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2026. PMID: 36251810."},{"key":"911_CR21","doi-asserted-by":"publisher","unstructured":"Arewa O. Evaluation of transfusion pyrexia: a review of differential diagnosis and management. ISRN Hematology. 2012;2012:524040. https:\/\/doi.org\/10.5402\/2012\/524040.","DOI":"10.5402\/2012\/524040"},{"key":"911_CR22","doi-asserted-by":"publisher","unstructured":"Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371:339\u201348. https:\/\/doi.org\/10.1056\/NEJMsa1311707.","DOI":"10.1056\/NEJMsa1311707"},{"key":"911_CR23","doi-asserted-by":"publisher","unstructured":"Rostami T, Kiumarsi A, Mohseni M. HSCT in Patients with Hemoglobinopathies. Cardiovascular considerations in hematopoietic stem cell transplantation. Springer. 2024;253\u201371. https:\/\/doi.org\/10.1007\/978-3-031-53659-5_19.","DOI":"10.1007\/978-3-031-53659-5_19"},{"key":"911_CR24","doi-asserted-by":"publisher","unstructured":"Khan Z, Agarwal N, Bhurani D, Khan M. Risk Factors for hematopoietic stem cell transplantation-associated bone loss. Transplant Cell Ther. 2021;27:212\u201321. https:\/\/doi.org\/10.1016\/j.bbmt.2020.10.002.","DOI":"10.1016\/j.bbmt.2020.10.002"},{"key":"911_CR25","unstructured":"Broder M, Quock T, Chang E, Reddy S, Agarwal-Hashmi R, Arai S, et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits. 2017;10:366\u201374."},{"key":"911_CR26","doi-asserted-by":"publisher","unstructured":"Kanter J, Thompson A, Pierciey FJ, Hsieh M, Uchida N, Leboulch P, et al. Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study. Am J Hematol. 2023;98:11\u201322. https:\/\/doi.org\/10.1002\/ajh.26741.","DOI":"10.1002\/ajh.26741"},{"key":"911_CR27","doi-asserted-by":"publisher","unstructured":"Frangoul H, Altshuler D, Cappellini M, Chen Y-S, Domm J, Eustace B, et al. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-Thalassemia. N Engl J Med. 2021;384:252\u201360. https:\/\/doi.org\/10.1056\/NEJMoa2031054.","DOI":"10.1056\/NEJMoa2031054"},{"key":"911_CR28","doi-asserted-by":"publisher","unstructured":"Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, et al. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med [Internet]. 2024; https:\/\/doi.org\/10.1056\/NEJMoa2309676.","DOI":"10.1056\/NEJMoa2309676"},{"key":"911_CR29","doi-asserted-by":"publisher","unstructured":"Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li A, et al. Exagamglogene autotemcel for transfusion-dependent \u03b2-Thalassemia. N Engl J Med. 2024;390:1663\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2309673.","DOI":"10.1056\/NEJMoa2309673"},{"key":"911_CR30","doi-asserted-by":"publisher","unstructured":"Locatelli F, Thompson A, Kwiatkowski J, Porter J, Thrasher A, Hongeng S, et al. Betibeglogene autotemcel gene therapy for non-\u03b20\/\u03b20 genotype \u03b2-Thalassemia. N Engl J Med. 2022;386:415\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2113206.","DOI":"10.1056\/NEJMoa2113206"},{"key":"911_CR31","doi-asserted-by":"publisher","unstructured":"Whitney D, Shestopalov I, Fincker M, d\u2019Anjou M, Kral K, Gayron M, et al. Drug product attributes predict clinical efficacy in betibeglogene autotemcel gene therapy for \u03b2-thalassemia. Mol Ther Methods clin dev. 2023;31:101155. https:\/\/doi.org\/10.1016\/j.omtm.2023.101155.","DOI":"10.1016\/j.omtm.2023.101155"},{"key":"911_CR32","doi-asserted-by":"publisher","unstructured":"Chetlapalli K, Butt A, Ito S, Wang D, Calhoun C, Krishnamurti L, et al. Deciding between multiple curative options in sickle cell disease: Cost-effectiveness of non-myeloablative\/reduced intensity conditioning haploidentical Allo-HSCT vs gene therapy vs standard of care in adult patients with sickle cell disease. Blood. 2024;144:601\u2013601. https:\/\/doi.org\/10.1182\/blood-2024-203234.","DOI":"10.1182\/blood-2024-203234"},{"key":"911_CR33","doi-asserted-by":"publisher","unstructured":"Cancellieri S, Zeng J, Lin L, Tognon M, Nguyen M, Lin J, et al. Human genetic diversity alters off-target outcomes of therapeutic gene editing. Nat Genet. 2023;55:34\u201343. https:\/\/doi.org\/10.1038\/s41588-022-01257-y.","DOI":"10.1038\/s41588-022-01257-y"},{"key":"911_CR34","doi-asserted-by":"publisher","unstructured":"Dong A, Rivella S, Breda L. Gene therapy for hemoglobinopathies: progress and challenges. Transl Res. 2013;161:293. https:\/\/doi.org\/10.1016\/j.trsl.2012.12.011.","DOI":"10.1016\/j.trsl.2012.12.011"},{"key":"911_CR35","doi-asserted-by":"publisher","unstructured":"Herring W, Gallagher M, Shah N, Morse K, Mladsi D, Dong O, et al. Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States. PharmacoEconomics. 2024;42:693\u2013714. https:\/\/doi.org\/10.1007\/s40273-024-01385-9.","DOI":"10.1007\/s40273-024-01385-9"},{"key":"911_CR36","unstructured":"Center for Drug Evaluation and Research. FDA approves luspatercept-aamt for anemia in patients with beta thalassemia [Internet]. U.S. Food and Drug Administration; 2024 [cited 2025 Mar 30]. Accessed 30 Mar 2025 https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-luspatercept-aamt-anemia-patients-beta-thalassemia."},{"key":"911_CR37","doi-asserted-by":"publisher","unstructured":"De Souza D, Hebert N, Esrick E, Ciuculescu M, Archer N, Armant M, et al. Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sickling. Nat Commun. 2023;14:1\u201310 https:\/\/doi.org\/10.1038\/s41467-023-40923-5.","DOI":"10.1038\/s41467-023-40923-5"},{"key":"911_CR38","doi-asserted-by":"publisher","unstructured":"L\u00f3pez Rubio M, Arg\u00fcello Marina M. The Current role of hydroxyurea in the treatment of sickle cell anemia. J Clin Med. 2024;13:6404 https:\/\/doi.org\/10.3390\/jcm13216404.","DOI":"10.3390\/jcm13216404"},{"key":"911_CR39","doi-asserted-by":"publisher","unstructured":"Saunthararajah Y, DeSimone J. Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease. Semin Hematol. 2004;41:11\u20136 https:\/\/doi.org\/10.1053\/j.seminhematol.2004.08.003.","DOI":"10.1053\/j.seminhematol.2004.08.003"},{"key":"911_CR40","doi-asserted-by":"publisher","unstructured":"Moutouh-de Parseval L, Verhelle D, Glezer E, Jensen-Pergakes K, Ferguson G, Corral L, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest. 2008;118:248\u201358. https:\/\/doi.org\/10.1172\/JCI32322.","DOI":"10.1172\/JCI32322"},{"key":"911_CR41","doi-asserted-by":"publisher","unstructured":"Gilmartin A, Groy A, Gore E, Atkins C, Long E, Montoute M, et al. In vitro and in vivo induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor. Haematologica. 2021;106:1979\u201387. https:\/\/doi.org\/10.3324\/haematol.2020.248658.","DOI":"10.3324\/haematol.2020.248658"},{"key":"911_CR42","doi-asserted-by":"publisher","unstructured":"Sasso J, Tenchov R, Wang D, Johnson L, Wang X, Zhou Q. Molecular glues: the adhesive connecting targeted protein degradation to the clinic. Biochem. 2023;62:601\u201323. https:\/\/doi.org\/10.1021\/acs.biochem.2c00245.","DOI":"10.1021\/acs.biochem.2c00245"},{"key":"911_CR43","doi-asserted-by":"publisher","unstructured":"Graham H. The mechanism of action and clinical value of PROTACs: A graphical review. Cell Signal. 2022;99:110446. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110446.","DOI":"10.1016\/j.cellsig.2022.110446"},{"key":"911_CR44","doi-asserted-by":"publisher","unstructured":"Sun X, Gao H, Yang Y, He M, Wu Y, Song Y, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019;4:64. https:\/\/doi.org\/10.1038\/s41392-019-0101-6.","DOI":"10.1038\/s41392-019-0101-6"},{"key":"911_CR45","doi-asserted-by":"publisher","unstructured":"Burke M, Smith A, Zheng G. Overcoming cancer drug resistance utilizing PROTAC technology. Front Cell Dev Biol. 2022;10:872729. https:\/\/doi.org\/10.3389\/fcell.2022.872729.","DOI":"10.3389\/fcell.2022.872729"},{"key":"911_CR46","doi-asserted-by":"publisher","unstructured":"Zhao L, Zhao J, Zhong K, Tong A, Jia D. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther. 2022;7:1\u201313. https:\/\/doi.org\/10.1038\/s41392-022-00966-4.","DOI":"10.1038\/s41392-022-00966-4"},{"key":"911_CR47","doi-asserted-by":"publisher","unstructured":"Shen C, Nayak A, Neitzel L, Adams A, Silver-Isenstadt M, Sawyer L, et al. The E3 ubiquitin ligase component, cereblon, is an evolutionarily conserved regulator of Wnt signaling. Nat Commun. 2021;12:5263. https:\/\/doi.org\/10.1038\/s41467-021-25634-z.","DOI":"10.1038\/s41467-021-25634-z"},{"key":"911_CR48","doi-asserted-by":"publisher","unstructured":"Tan X, Huang Z, Pei H, Jia Z, Zheng J. Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development. iScience. 2024;27:110712. https:\/\/doi.org\/10.1016\/j.isci.2024.110712.","DOI":"10.1016\/j.isci.2024.110712"},{"key":"911_CR49","doi-asserted-by":"publisher","unstructured":"Kurimchak A, Herrera-Mont\u00e1vez C, Montserrat-Sangr\u00e0 S, Araiza-Olivera D, Hu J, Neumann-Domer R, et al. The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. Sci Signal. 2022;15:eabn2707. https:\/\/doi.org\/10.1126\/scisignal.abn2707.","DOI":"10.1126\/scisignal.abn2707"},{"key":"911_CR50","doi-asserted-by":"publisher","unstructured":"Wolf G, Craigon C, Teoh S, Essletzbichler P, Onstein S, Cassidy D, et al. The efflux pump ABCC1\/MRP1 constitutively restricts PROTAC sensitivity in cancer cells. Cell Chem Biol. 2025;32:291\u2013306.e6. https:\/\/doi.org\/10.1016\/j.chembiol.2024.11.009.","DOI":"10.1016\/j.chembiol.2024.11.009"},{"key":"911_CR51","doi-asserted-by":"publisher","unstructured":"HoldgateG, Bardelle C, Berry S, Lanne A, Cuomo M. Screening for molecular glues - Challenges and opportunities. SLAS Discovery. 2024;29:100136. https:\/\/doi.org\/10.1016\/j.slasd.2023.12.008.","DOI":"10.1016\/j.slasd.2023.12.008"},{"key":"911_CR52","doi-asserted-by":"publisher","unstructured":"Zeng S, Huang W, Zheng X, Liyan Cheng, Zhang Z, Wang J, et al. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges. Eur J Med Chem. 2021;210:112981. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112981.","DOI":"10.1016\/j.ejmech.2020.112981"},{"key":"911_CR53","doi-asserted-by":"publisher","unstructured":"Kostic M, Jones L. Critical assessment of targeted protein degradation as a research tool and pharmacological modality. Trends Pharmacol Sci. 2020;41:305\u201317. https:\/\/doi.org\/10.1016\/j.tips.2020.02.006.","DOI":"10.1016\/j.tips.2020.02.006"},{"key":"911_CR54","doi-asserted-by":"publisher","unstructured":"Kozicka Z, Thom\u00e4 N. Haven\u2019t got a glue: Protein surface variation for the design of molecular glue degraders. Cell Chem Biol. 2021;28:1032\u201347. https:\/\/doi.org\/10.1016\/j.chembiol.2021.04.009.","DOI":"10.1016\/j.chembiol.2021.04.009"},{"key":"911_CR55","doi-asserted-by":"publisher","unstructured":"Bever C, Dong J-X, Vasylieva N, Barnych B, Cui Y, Xu Z-L, et al. VHH antibodies: emerging reagents for the analysis of environmental chemicals. Anal Bioanal Chem. 2016;408:5985\u20136002 https:\/\/doi.org\/10.1007\/s00216-016-9585-x.","DOI":"10.1007\/s00216-016-9585-x"},{"key":"911_CR56","doi-asserted-by":"publisher","unstructured":"Zhang H, Han Y, Yang Y, Lin F, Li K, Kong L, et al. Covalently engineered nano-body chimeras for targeted membrane protein degradation. J Am Chem Soc. 2021;143:16377\u201382. https:\/\/doi.org\/10.1021\/jacs.1c08521.","DOI":"10.1021\/jacs.1c08521"},{"key":"911_CR57","doi-asserted-by":"publisher","unstructured":"Ma S, Ji J, Tong Y, Zhu Y, Dou J, Zhang X, et al. Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope. Acta Pharmaceutica Sinica B. 2022;12:2990\u20133005. https:\/\/doi.org\/10.1016\/j.apsb.2022.02.022.","DOI":"10.1016\/j.apsb.2022.02.022"},{"key":"911_CR58","doi-asserted-by":"publisher","unstructured":"Shen F, Dassama L. Opportunities and challenges of protein-based targeted protein degradation. Chem Sci. 2023;14:8433\u201347. https:\/\/doi.org\/10.1039\/D3SC02361C.","DOI":"10.1039\/D3SC02361C"},{"key":"911_CR59","doi-asserted-by":"publisher","unstructured":"Kunishige R, Murata M, Kano F. Targeted protein degradation by Trim-Away using cell resealing coupled with microscopic image-based quantitative analysis. Front Cell Dev Biol. 2022;10:1027043. https:\/\/doi.org\/10.3389\/fcell.2022.1027043.","DOI":"10.3389\/fcell.2022.1027043"},{"key":"911_CR60","doi-asserted-by":"publisher","unstructured":"Clift D, McEwan W, Labzin L, Konieczny V, Mogessie B, James L, et al. A method for the acute and rapid degradation of endogenous proteins. Cell. 2017;171:1692\u20131706.e18. https:\/\/doi.org\/10.1016\/j.cell.2017.10.033.","DOI":"10.1016\/j.cell.2017.10.033"},{"key":"911_CR61","doi-asserted-by":"publisher","unstructured":"Vunjak M, Versteeg G. TRIM proteins. Current Biology. 2019;29:R42\u20134. https:\/\/doi.org\/10.1016\/j.cub.2018.11.026.","DOI":"10.1016\/j.cub.2018.11.026"},{"key":"911_CR62","doi-asserted-by":"publisher","unstructured":"Wang H, Zhou R, Xu F, Yang K, Zheng L, Zhao P, et al. Beyond canonical PROTAC: biological targeted protein degradation (bioTPD). Biomater Res. 2023;27:72. https:\/\/doi.org\/10.1186\/s40824-023-00385-8.","DOI":"10.1186\/s40824-023-00385-8"},{"key":"911_CR63","doi-asserted-by":"publisher","unstructured":"Feng X, Wang H. Emerging landscape of nanobodies and their neutralizing applications against SARS-CoV-2 virus. ACS Pharmacol Transl Sci. 2023;6:925\u201342. https:\/\/doi.org\/10.1021\/acsptsci.3c00042.","DOI":"10.1021\/acsptsci.3c00042"},{"key":"911_CR64","doi-asserted-by":"publisher","unstructured":"Groeve K, Deschacht N, De Koninck C, Caveliers V, Lahoutte T, Devoogdt N, et al. Nanobodies as tools for in vivo imaging of specific immune cell types. J Nucl Med. 2010;51:782\u20139. https:\/\/doi.org\/10.2967\/jnumed.109.070078.","DOI":"10.2967\/jnumed.109.070078"},{"key":"911_CR65","doi-asserted-by":"publisher","unstructured":"Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, et al. Single domain antibodies: promising experimental and therapeutic tools in infec-tion and immunity. Med Microbiol Immunol. 2009;198:157\u201374. https:\/\/doi.org\/10.1007\/s00430-009-0116-7.","DOI":"10.1007\/s00430-009-0116-7"},{"key":"911_CR66","doi-asserted-by":"publisher","unstructured":"Tao Z, Zhao X, Wang H, Zhang J, Jiang G, Yu B, et al. A method for rapid nanobody screening with no bias of the library diversity. bioRxiv [Internet]. 2023. https:\/\/doi.org\/10.1101\/2023.02.15.528753.","DOI":"10.1101\/2023.02.15.528753"},{"key":"911_CR67","doi-asserted-by":"publisher","unstructured":"Dhaouadi S, Ben Abderrazek R, Loustau T, Abou-Faycal C, Ksouri A, Erne W, et al. Novel human tenascin-C function-blocking camel single domain nanobodies. Front Immunol. 2021;12:635166. https:\/\/doi.org\/10.3389\/fimmu.2021.635166.","DOI":"10.3389\/fimmu.2021.635166"},{"key":"911_CR68","doi-asserted-by":"publisher","unstructured":"Ji P, Zhu J, Li X, Fan W, Liu Q, Wang K, et al. Fenobody and RANbody-based sandwich enzyme-linked immunosorbent assay to detect Newcastle disease virus. J Nanobiotechnology. 2020;18:44. https:\/\/doi.org\/10.1186\/s12951-020-00598-2.","DOI":"10.1186\/s12951-020-00598-2"},{"key":"911_CR69","doi-asserted-by":"publisher","unstructured":"Powars D, Weiss J, Chan L, Schroeder W. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood. 1984;63:921\u20136. https:\/\/doi.org\/10.1182\/blood.V63.4.921.921.","DOI":"10.1182\/blood.V63.4.921.921"},{"key":"911_CR70","doi-asserted-by":"publisher","unstructured":"Musallam K, Sankaran V, Cappellini M, Duca L, Nathan D, Taher A. Fetal hemoglobin levels and morbidity in untransfused patients with \u03b2-thalassemia intermedia. Blood. 2012;119:364\u20137. https:\/\/doi.org\/10.1182\/blood-2011-09-382408.","DOI":"10.1182\/blood-2011-09-382408"},{"key":"911_CR71","doi-asserted-by":"publisher","unstructured":"Verheul T, Trinh V, V\u00e1zquez O, Philipsen S. Targeted protein degradation as a promising tool for epigenetic upregulation of fetal hemoglobin. ChemMedChem. 2020;15:2436\u201343. https:\/\/doi.org\/10.1002\/cmdc.202000574.","DOI":"10.1002\/cmdc.202000574"},{"key":"911_CR72","doi-asserted-by":"publisher","unstructured":"Bou-Fakhredin R, De Franceschi L, Motta I, Cappellini M, Taher A. Pharmacological Induction of Fetal Hemoglobin in \u03b2-Thalassemia and Sickle Cell Disease: An Updated Perspective. Pharmaceuticals. 2022;15. https:\/\/doi.org\/10.3390\/ph15060753.","DOI":"10.3390\/ph15060753"},{"key":"911_CR73","doi-asserted-by":"publisher","unstructured":"Nabet B, Roberts J, Buckley D, Paulk J, Dastjerdi S, Yang A, et al. The dTAG system for immediate and target-specific protein degradation. Nat Chem Biol. 2018;14:431\u201341. https:\/\/doi.org\/10.1038\/s41589-018-0021-8.","DOI":"10.1038\/s41589-018-0021-8"},{"key":"911_CR74","doi-asserted-by":"publisher","unstructured":"Shen F, Zheng G, Setegne M, Tenglin K, Izadi M, Xie H, et al. A cell-permeant nanobody-based degrader that induces fetal hemoglobin. ACS Cent Sci. 2022;8:1695\u2013703. https:\/\/doi.org\/10.1021\/acscentsci.2c00998.","DOI":"10.1021\/acscentsci.2c00998"},{"key":"911_CR75","doi-asserted-by":"publisher","unstructured":"Yin M, Izadi M, Tenglin K, Viennet T, Zhai L, Zheng G, et al. Evolution of nanobodies specific for BCL11A. Proc Natl Acad Sci USA. 2023;120:e2218959120. https:\/\/doi.org\/10.1073\/pnas.2218959120.","DOI":"10.1073\/pnas.2218959120"},{"key":"911_CR76","doi-asserted-by":"publisher","unstructured":"Yang H, Zheng G, Li G, Alshaye A, Orkin S. Redirecting E3 ubiquitin ligases for targeted protein degradation with heterologous recognition domains. J Biol Chem. 2025;301:108077. https:\/\/doi.org\/10.1016\/j.jbc.2024.108077.","DOI":"10.1016\/j.jbc.2024.108077"},{"key":"911_CR77","doi-asserted-by":"publisher","unstructured":"Jang Y, Feng R, Palmer L, Mayuranathan T, Yao Y, Mayberry K, et al. BCL11A-deficient human erythropoiesis is impaired in vitro and after xenotransplantation into mice. Blood Adv. 2025;9:2722\u201332. https:\/\/doi.org\/10.1182\/bloodadvances.2024015574.","DOI":"10.1182\/bloodadvances.2024015574"},{"key":"911_CR78","doi-asserted-by":"publisher","unstructured":"Liu J, Shen Z, Park S-Y, Dong Y, Yu N, Zeng J, et al. Discovery of A small molecule non-IMiD degrader of ZBTB7A for the treatment of \u03b2-hemoglobinopathies. bioRxiv [Internet]. 2025. https:\/\/doi.org\/10.1101\/2025.09.17.676148.","DOI":"10.1101\/2025.09.17.676148"},{"key":"911_CR79","doi-asserted-by":"publisher","unstructured":"Higgs D, Kassouf M. Developing a pill to treat sickle cell disease. Science. 2024;385:27\u20138. https:\/\/doi.org\/10.1126\/science.adq3757.","DOI":"10.1126\/science.adq3757"},{"key":"911_CR80","unstructured":"ClinicalTrials.gov. A phase I\/II study of ITU512 in healthy participants and patients with sickle cell disease [Internet]. National Library of Medicine; 2026 [cited 2025 July 18]. Accessed 18 July 2025. https:\/\/clinicaltrials.gov\/study\/NCT06546670."},{"key":"911_CR81","unstructured":"GluBio Therapeutics. Science & Innovation [Internet]. GluBio Therapeutics; 2024. https:\/\/www.glubiotx.com\/en\/science--innovation."},{"key":"911_CR82","doi-asserted-by":"publisher","unstructured":"Rychak E, Lui G, Fimbres C, Kang C, Sun Y, Peng S, et al. Development of a ZBTB7A and Wiz Dual Degrating, HbF-Activating CELMoD\u2122 for the Treatment of Sickle Cell Disease. Blood. 2024;144:169. https:\/\/doi.org\/10.1182\/blood-2024-203653.","DOI":"10.1182\/blood-2024-203653"},{"key":"911_CR83","unstructured":"ClinicalTrials.gov.A study to evaluate BMS-986470 in healthy volunteers and participants with sickle cell disease [Internet]. National Library of Medicine; 2026 [cited 2025 July 18]. Accessed 18 July 2025. https:\/\/clinicaltrials.gov\/study\/NCT06481306?intr=BMS-986470%20&rank=1."},{"key":"911_CR84","doi-asserted-by":"publisher","unstructured":"Samarasinghe K, Jaime-Figueroa S, Burgess M, Nalawansha D, Dai K, Hu Z, et al. Targeted degradation of transcription factors by traftacs: transcription factor targeting chimeras. Cell Chem Biol. 2021;28:648-661.e5. https:\/\/doi.org\/10.1016\/j.chembiol.2021.03.011.","DOI":"10.1016\/j.chembiol.2021.03.011"},{"key":"911_CR85","doi-asserted-by":"publisher","unstructured":"Hsia O, Hinterndorfer M, Cowan A, Iso K, Ishida T, Sundaramoorthy R, et al. Targeted protein degradation via intramolecular bivalent glues. Nature. 2024;627:204\u201311. https:\/\/doi.org\/10.1038\/s41586-024-07089-6.","DOI":"10.1038\/s41586-024-07089-6"},{"key":"911_CR86","doi-asserted-by":"publisher","unstructured":"He Q, Zhao X, Wu D, Jia S, Liu C, Cheng Z, et al. Hydrophobic tag-based protein degradation: development, opportunity and challenge. Eur J Med Chem. 2023;260:115741. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115741.","DOI":"10.1016\/j.ejmech.2023.115741"},{"key":"911_CR87","doi-asserted-by":"publisher","unstructured":"Zhong G, Chang X, Xie W, Zhou X. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct Target Ther. 2024;9:308. https:\/\/doi.org\/10.1038\/s41392-024-02004-x.","DOI":"10.1038\/s41392-024-02004-x"},{"key":"911_CR88","doi-asserted-by":"publisher","unstructured":"Guo L, Zhou Y, Nie X, Zhang Z, Zhang Z, Li C, et al. A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions. Eur J Med Chem. 2022;236:114317. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114317.","DOI":"10.1016\/j.ejmech.2022.114317"},{"key":"911_CR89","doi-asserted-by":"publisher","unstructured":"Chen J, Wu M, Mo J, Hong J, Wang W, Jin Y, et al. Auto-RapTAC: A versatile and sustainable platform for the automated rapid synthesis and evaluation of PROTAC. J Med Chem. 2025;68:8010\u201324. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02438.","DOI":"10.1021\/acs.jmedchem.4c02438"},{"key":"911_CR90","doi-asserted-by":"publisher","unstructured":"Rovers E, Schapira M. Methods for computer-assisted PROTAC design. Methods in Enzymology. 2023. p. 311\u201340. https:\/\/doi.org\/10.1016\/bs.mie.2023.06.020.","DOI":"10.1016\/bs.mie.2023.06.020"},{"key":"911_CR91","doi-asserted-by":"publisher","unstructured":"Mslati H, Gentile F, Pandey M, Ban F, Cherkasov A. Protacable Is an Integrative computational pipeline of 3-D modeling and deep learning to automate the de novo design of protacs J Chem Inf Model. 2024;64:3034\u201346. https:\/\/doi.org\/10.1021\/acs.jcim.3c01878.","DOI":"10.1021\/acs.jcim.3c01878"},{"key":"911_CR92","doi-asserted-by":"publisher","unstructured":"Izaguirre J, Wu Y, McDargh Z, Palpant T, Razavi A, Trovato F, et al. Computational modeling of ternary complex formation and targeted protein degradation mediated by molecular glues. bioRxiv [Internet]. 2025. https:\/\/doi.org\/10.1101\/2025.01.13.632817.","DOI":"10.1101\/2025.01.13.632817"},{"key":"911_CR93","doi-asserted-by":"publisher","unstructured":"Liu X, Wang A, Shi Y, Dai M, Liu M, Cai H. Protacs in epigenetic cancer therapy: current status and future opportunities. Mol. 2023;28. https:\/\/doi.org\/10.3390\/molecules28031217.","DOI":"10.3390\/molecules28031217"},{"key":"911_CR94","doi-asserted-by":"publisher","unstructured":"Yang J-P, Toughiri R, Gounder A, Scheibe D, Petrus M, Fink S, et al. Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell disease. PLoS One. 2024;19:e0307049. https:\/\/doi.org\/10.1371\/journal.pone.0307049.","DOI":"10.1371\/journal.pone.0307049"},{"key":"911_CR95","doi-asserted-by":"publisher","unstructured":"SunY, Benmhammed H, Al Abdullatif S, Habara A, Fu E, Brady J, et al. PGC-1\u03b1 agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell disease. Sci Adv. 2024;10:eadn8750. https:\/\/doi.org\/10.1126\/sciadv.adn8750.","DOI":"10.1126\/sciadv.adn8750"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00911-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00911-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00911-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T10:04:26Z","timestamp":1780826666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00911-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["911"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00911-5","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"23 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}